TABLE 1.
Demographics and baseline characteristics
| Somapacitan | Daily GH | Total | |
|---|---|---|---|
| Number of patients | 46 | 16 | 62 |
| Age (years) | |||
| Mean (SD) | 54.1 (12.1) | 49.3 (11.5) | 52.8 (12.1) |
| Min–max | 20‐75 | 32‐71 | 20‐75 |
| Sex, n (%) | |||
| Female | 22 (47.8) | 7 (43.8) | 29 (46.8) |
| Male | 24 ( 52.2) | 9 ( 56.3) | 33 ( 53.2) |
| GHD onset, n (%) | |||
| Childhood—idiopathic | 4 (8.7) | 1 (6.3) | 5 (8.1) |
| Childhood—organic | 5 (10.9) | 1 (6.3) | 6 (9.7) |
| Adulthood | 37 (80.4) | 14 (87.5) | 51 (82.3) |
| Body weight (kg) | |||
| Mean (SD) | 69.4 (22.7) | 67.9 (12.0) | 69.0 (20.4) |
| Min‐max | 34.5‐150.5 | 54.0‐93.3 | 34.5‐150.5 |
| BMI (kg/m2) | |||
| Mean (SD) | 26.4 (6.7) | 24.8 (3.7) | 26.0 (6.1) |
| Min‐max | 17.0‐51.9 | 19.2‐32.8 | 17.0‐51.9 |
| Abdominal adipose tissue compartments, mean (SD) (cm2) | |||
| VAT | 109.24 (77.23) | 90.57 (38.99) | ‐ |
| SAT | 238.75 (167.03) | 185.92 (79.37) | ‐ |
| TAT | 347.99 (220.26) | 276.49 (111.23) | ‐ |
| IGF‐I SDS | 0.64 | 0.88 | ‐ |
| GH dose at screening (mg) | |||
| Mean (SD) | 0.31 (0.17) | 0.29 (0.14) | 0.31 (0.16) |
| Min‐max | 0.05‐1.00 | 0.20‐0.70 | 0.05‐1.00 |
| Duration of current GH treatment (years) | |||
| Mean (SD) | 2.02 (1.85) | 1.77 (1.14) | 1.95 (1.69) |
| Min‐max | 0.53‐7.27 | 0.56‐3.92 | 0.53‐7.27 |
Abbreviations: BMI, body mass index; GH, growth hormone; GHD, growth hormone deficiency; IGF‐I SDS, insulin‐like growth factor‐I standard deviation score; SAT, subcutaneous adipose tissue; TAT, total adipose tissue; VAT, visceral adipose tissue.